Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis

Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Multiple sclerosis international 03/2013; 2013:189624. DOI: 10.1155/2013/189624
Source: PubMed


Sustained progression on the expanded disability status scale (EDSS) is a common outcome measure of disease progression in clinical studies of MS. Unfortunately, this outcome may not accurately measure long-term and irreversible disease progression. To assess the performance of definitions of sustained progression, patients with relapsing-remitting MS (RRMS) or a clinically isolated syndrome with evidence of lesions on a brain MRI were included in our study. Fifteen definitions of sustained progression using both the EDSS and the functional system (FS) scales were investigated. The impact of both relapses and changes in provider on the probability of maintaining progression was also evaluated. Although the provider scoring the EDSS sometimes changed during followup, the provider had access to previous EDSS scores. Between 15.8% and 42.2% of patients experienced sustained progression based on the definitions using EDSS as the outcome, but nearly 50% of these patients failed to maintain sustained progression for the duration of followup. When FS scales were used, progression was most common on the pyramidal and sensory scales. Unfortunately, progression on specific FS scales failed to be more sensitive to irreversible disability. Relapses or changes in provider did not explain the poor performance of the measures. Short-term changes in the EDSS or FS scores may not be an accurate marker of irreversible change in RRMS.

Download full-text


Available from: Alexander Musallam
  • [Show abstract] [Hide abstract]
    ABSTRACT: Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they have limitations that may affect our perception of disease progression either due to the empirical nature of some assessments or the lack of validation with long-term outcomes. Measuring effects on disability accumulation in relapsing-remitting MS is also difficult in clinical trial situations because of the protracted evolution of the disease and the ethical and practical implications of long-term placebo-controlled trials, which may have implications for clinicians considering treatment options. Despite these issues, interferon-beta therapies have decades of follow-up data, with which it is possible to evaluate prognostic factors for the accumulation of disability in relapsing-remitting MS.
    No preview · Article · Jan 2014 · Expert Review of Neurotherapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Latin American MS Experts’ Forum has developed practical recommendations on the initiation and optimization of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The recommendations reflect the unique epidemiology of MS and the clinical practice environment in Latin American countries. Treatment response may be evaluated according to changes in relapses; progression, as assessed by the Expanded Disability Status Scale and the Timed 25-foot Walk; and lesion number on magnetic resonance imaging. Follow-up assessments are recommended every six months, or annually for stable patients. Cognitive function should be evaluated in all RRMS patients at baseline and annually thereafter. These recommendations are intended to assist clinicians in Latin America in developing a rational approach to treatment selection and sequencing for their RRMS patients.
    Full-text · Article · Apr 2014 · Journal of the neurological sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: The clinical trial design for primary progressive multiple sclerosis (PPMS) requires understanding of disability progression in modern patient cohorts. Objective: The objective of this paper is to characterize demographic and clinical characteristics of PPMS and assess rate of disability progression. Methods: We studied PPMS (n = 73) and relapsing-onset MS (ROMS) patients (n = 1541) enrolled in CLIMB, a longitudinal study of MS patients at the Brigham and Women's Hospital (Boston, MA). Disability progression for each group was compared using interval-censored survival analysis and time to six-month sustained progression. Results: The PP group had a 1.09:1 male:female ratio compared to 1:2.89 for the RO group and greater mean age of onset (PP: 44.49.6; RO: 32.7 +/- 9.9; p < 0.0001). Motor symptoms at onset and first symptoms localized to spinal cord were each strongly associated with PPMS (p < 0.001). Median time from onset to EDSS 6.0 was faster in PPMS (p < 0.001). PPMS patients progressed faster to EDSS 3 (p < 0.001) and from EDSS 3 to 6 (p < 0.001). Median time to sustained progression in the PP group was 4.85 years (95% CI 2.83-8.35), significantly faster than the RO group (p < 0.001). Conclusions: Our modern PPMS cohort is demographically similar to previously studied cohorts. PPMS is associated with faster disability accrual than ROMS. Current real-world observations of time to sustained progression will inform design of new clinical trials for PPMS.
    No preview · Article · Jul 2014 · Multiple Sclerosis
Show more